NEUP

$3.83-$0.00 (-0.13%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$20.6M

5M shares

52-week range

$3.19 – $21.40

3% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

ADRC

Change$-2.80

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$6M	-39.7%	$-2.43	$-2.43–$-2.43	—	1
2028	$57M	+900.4%	$-2.46	$-2.46–$-2.46	—	1
2029	$57M	+0.5%	$-5.05	$-5.05–$-5.05	—	1
2030	$61M	+7.2%	$-2.14	$-2.14–$-2.14	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-15	$-0.56	$-0.09	+83.9%
2026-02-17	$-0.56	$-0.77	-37.5%
2025-11-14	$-0.55	$-4.41	-701.8%
2025-09-29	$-0.56	$-5.79	-933.9%
2025-05-20	$-0.47	$6.55	+1493.6%
2025-03-17	$-2.01	$-0.01	+99.6%
2024-09-30	$-11.38	$-29.16	-156.2%

DCF fair valuemodel estimate

Intrinsic value

$21.31

Price

$3.83

Implied upside

+457%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NEUPNeuphoria Therapeutics Inc.	$3.83	+0.13%	$21M	—
ALZNAlzamend Neuro Inc	$1.45	-0.68%	$6M	—
APREAprea Therapeutics, Inc.	$0.68	+1.34%	$8M	—
BCDABioCardia, Inc.	$0.94	+0.68%	$14M	—
BMRABiomerica, Inc.	$1.53	-5.56%

Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

www.neuphoriatx.com

Employees: 8
IPO / List date: Dec 16, 2021
HQ: BURLINGTON, MA

Held by traders on TradeandTell

No one on the platform currently holds NEUP.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in NEUP as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NEUP yet.

$NEUP chatter on StockTwits

Jose Berrios@dario2580Bullish6d
$NEUP Clinical-stage pipeline = major upside if trials succeed..
View on StockTwits ↗
Lucia Rehakova@Quido22BullishJul 30
$NEUP soo. When I hold until the merger with scancell and then sell I will still be eligible to get the CVRs. Did I understand correctly?
View on StockTwits ↗
Manu CV@marnoflesJul 25
$NEUP The CEO is a traitor. Whether this ends well or badly, he's a traitor. I'll be out as soon as I can.
View on StockTwits ↗
Dan@skyrockets_IncJul 24
$NEUP Sold 1/5 of my position to play some more $HOWL as news is imminent there. Plan to buy back my shares and maybe more afterwards. Not selling on any negativity, just think this may linger for a few more weeks and want my money to go to work elsewhere then come back. I still think LYNX will buy BNC210 , just no way to be able to predict when that will happen. Is it more likely to happen before or after the poison pill in late Oct? Thoughts?
View on StockTwits ↗
Lucia Rehakova@Quido22Jul 24
$NEUP I was away. What did change after yesterday optimism?
View on StockTwits ↗
Giuseppe@joe77wJul 24
$NEUP uk placement at 9p or 0.09, il shareholders shocked by Exchange ratio terms, I have read their messages a lot of times many SCANCELL holders were not willing to pay 10 or 20 shares for 1 NEUP now are seeing 37.7 shares granted for each NEUP. They were wrong assuming NEUP a Shell and only NASDAQ listing to pay so NEUP Will give them 10 mln at least to fund R&D.
View on StockTwits ↗
Giuseppe@joe77wJul 24
$NEUP according current merger Exchange ratio NEUP pps assumes SCANCELL pps at .075 while now trading at .095. SCANCELL was trading at .18 when news leaked and .29 in the early spring, funding issues killed the stock, science very promising .
View on StockTwits ↗
Giuseppe@joe77wJul 24
$NEUP BNC 210 and Carina Biotech dismissed or what?
View on StockTwits ↗
Biotech Pharma Investor@Biotech_Pharma_InvestorJul 24
$NEUP What is troubling about thus deal is the near 30% discount in the pricing of the PIPE compared to the pre-announcement price of Scancell. Also pretty small PIPE for a ph3 company with this piepeline + debt..
View on StockTwits ↗
Lima B@Lima2111Jul 24
$NEUP 8-K Summary — July 24 Merger valuations: Scancell $144.6M, NEUP $24.6M. NEUP holders get 11.1% fully diluted. Per share scenarios: • Pre-money: $3.48 • Post-money floor: $4.72 • Post-money max: $5.11 Armistice (warrant holder, invisible in 13D/G filings) takes $3.5M cash guaranteed at closing. CVRs: Merck, KAT6/Pfizer, IP monetisation, R&D tax credit — 100% net proceeds, 15 years, non-transferable, no guarantee. Bull case: Trinity Delta £382M Scancell fair value → ~$10.50/share post-NASDAQ re-rating. 12-24 month story. ❓ Open questions: 1. Board rejected $4.75 Lynx cash — how is $3.48-5.11 superior? 2. Lynx agreed to lock-up at 16.3% — BNC210 side deal post poison expiry? 3. BNC210 PTSD absent from CVR despite Phase 3-ready + FDA Fast Track 4. Superior Offer clause retained 5. Form F-4 proxy in 4-8 weeks — watch for side arrangements
View on StockTwits ↗
Top Stock Alerts@topstockalertsJul 23
$NEUP this is actually holding up way better than I thought
View on StockTwits ↗
Jadeite Needle@jadeite_haystackJul 23
$NEUP reversal imminent. Needa to hold above $2.12. 2 months max before she runs hard
View on StockTwits ↗
SpeccSpecx@speccthamJul 23
$NEUP Sell the merger news is statistically the best for small pharmacaps. Where yall think the price going after today? sideways for months? down?
View on StockTwits ↗
Dan@skyrockets_IncJul 23
$NEUP No PR from Neuphoria yet is strange and also another minor detail. They mention all potential future revenue generators in the CVR quote below except the CarinaBio Partnered asset , which still has potential to receive up to 70M in milestone payments. They specifically mention the Merck agreement, Australian CRC royalty agreement, tax credits, and potential asset sales (i.e. BNC210), but no mention of CNA3103.....strange.
View on StockTwits ↗
PennySearch@PennySearchJul 23
📈 Top Penny Stock Movers by Relative Volume $NEUP — 20.29x RVOL Move: +23% Volume: 6.8M (337.0K average) Market Cap: $21.9M Day Range: 3.68 – 4.12 52-Week Range: 3.19 – 21.40 $CJMB — 7.37x RVOL Move: +19% Volume: 26.9M (3.6M average) Market Cap: $9.6M Day Range: 1.80 – 2.98 52-Week Range: 0.65 – 5.61 $DOMO — 6.64x RVOL Move: +24% Volume: 23.7M (3.6M average) Market Cap: $163.6M Day Range: 3.73 – 4.44 52-Week Range: 1.84 – 18.49 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.